Pathway 2

Feb 12, 2021pathway-2 was a large multicenter, double-blind study randomly assigning patients with resistant hypertension to sequential therapy with spironolactone, doxazosin, bisoprolol, or. In the pathway-2 study of resistant hypertension, spironolactone reduced blood pressure substantially more than conventional antihypertensive drugs. Jan 1, 2023to determine whether a medical school’s students and recent graduates are eligible to apply to pathway 2, search the list of medical schools eligible for 2026 pathways.

The pathway-2 study provides the first direct comparative evaluation of three different four-drug antihypertensive regimens. Nov 5, 2024pathway-2 was a 12-month, double-blind, placebo-controlled, crossover trial, enrolling patients aged 18–79 years from the uk. Pathway-2 is the first rct to directly compare spironolactone with other active bp-lowering treatments in patients with well characterised resistant hypertension

Pathway 2 is a randomised, double blind, placebo-controlled, crossover, multicentre trial comparing the four treatment options for patients with resistant hypertension. Mar 8, 2018the recent pathway-2 trial demonstrated superior htn control when spironolactone was added as a 4th agent in rhtn. However, the applicability of pathway-2 in contemporary.

Nov 27, 2015pathway-2 is the first randomised controlled trial to compare spironolactone with other blood pressure-lowering drug treatments in a well-characterised population of patients with resistant. Aug 30, 2015the pathway-2 trial showed that spironolactone was the most effective add-on treatment for resistant hypertension.